Zeven (dalbavancin) / RaQualia, AbbVie  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zeven (dalbavancin) / RaQualia, AbbVie
NCT03696901: Xydalba Utilization Registry in Germany

Terminated
N/A
16
Europe
Xydalba, Dalbavancin
Correvio International Sarl, AMS Advanced Medical Services GmbH, PrimeVigilance
Bacterial Infections
03/20
04/20
NCT03726216: Xydalba Utilization Registry in France

Completed
N/A
151
Europe
Xydalba, Dalbavancine
Correvio International Sarl, Universal Medical Group, PrimeVigilance
Bacterial Infections
04/20
10/20
REAL-DAL, NCT04485676: Dalbavancin in Real Clinical Practice in Spain

Completed
N/A
187
Europe
Angelini Farmacéutica, Effice Servicios Para la Investigacion S.L.
Skin Diseases, Bacterial, Skin Diseases, Infectious
12/20
02/21
REDS, NCT04298463: Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI

Completed
N/A
184
Europe
Xydalba, vancomycin, teicoplanin or daptomycin
Aziende Chimiche Riunite Angelini Francesco S.p.A, Hippocrates Research
Acute Bacterial Skin and Skin Structure Infection
05/21
05/21
DALBADIA, NCT04959799: Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections

Completed
N/A
98
Europe
Dalbavancin, Xydalba
Aziende Chimiche Riunite Angelini Francesco S.p.A, Iqvia Pty Ltd
Diabetes, Infection
05/22
05/22
PRODALBA, NCT05046860: Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements

Recruiting
N/A
43
Europe
Dalbavancin
Centre Hospitalier Universitaire de Nice
Osteoarticular Infection
09/24
09/24
DALBASAT, NCT06089044: Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections

Completed
N/A
15
Europe
Dalbavancin Injection
Tourcoing Hospital
Prosthesis-related Infections
12/22
12/22
NCT04624451: Evaluation of Intravenous Dalbavancin for Peritonitis

Terminated
N/A
2
US
Dalbavancin
University of Colorado, Denver
Peritonitis, Peritonitis Bacterial
12/23
01/24
DALBA-SAT, NCT06899906: Efficacy and Safety of Dalbavancin As Suppressive Therapy

Recruiting
N/A
33
Europe
Determine patient demographic and clinical characteristics at baseline
Hospices Civils de Lyon
Efficacy and Safety of Dalbavancin, In Subjects Who Received SAT with DAL, For Acute or Chronic Infections Between July 2019 and December 2024
03/25
05/25

Download Options